Mytos Inc.

Overview

Mytos describes itself as an automated CDMO for regenerative medicines and a developer of iDEM automated tissue production systems. The company states that therapies work in the clinic but fail to scale because of manual production, and positions its automation as a way to scale in months rather than years.

Services and technology

• Automated contract manufacturing of stem-cell derived therapies
• iDEM automated cell production technology, described as in its sixth generation of iteration
• Proof of Value pilots: discovery, scoping, and a pilot run in Mytos labs to validate that a client's process can be automated and to demonstrate ROI

Reported performance

The website cites 4x faster scaling, 10x batches per cleanroom, 40% lower cost per batch, and 10x fewer FTE hours compared with manual production.

Activity and partners

Mytos reports manufacturing collaborations including Aspen Neuroscience in Parkinson's disease. Other featured partners are Novadip (bone repair), Rinri Therapeutics (hearing), and StemSight (vision). The company is based in London, UK, was founded in 2016, and has raised more than $35 million.